lunes, 28 de noviembre de 2016

Adult Non-Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute

Adult Non-Hodgkin Lymphoma Treatment (PDQ®)—Health Professional Version - National Cancer Institute
National Cancer Institute

Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version



SECTIONS

Changes to This Summary (11/22/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Kahl et al. as reference 8.
Added Zucca et al. as reference 59.
Added Thieblemont et al. as reference 90.
Added Arcaini et al. as reference 94.
Added text to state that patients with central nervous system dissemination at diagnosis or at relapse usually receive rituximab and high-doses of methotrexate and/or cytarabine followed by autologous stem cell transplantation, but this approach has not been assessed in randomized trials (cited Ferreri et al. as reference 31, Schmitz et al. as reference 32, and level of evidence 3iiiDiv).
Added Barrington et al. as reference 2.
Added text to state that the Lugano classification system eliminates the A and B categories for staging of NHL (cited Cheson et al. as reference 10).
Added text to state that several retrospective reviews suggest routine surveillance scans after attaining clinical complete remission after induction therapy for diffuse large B-cell lymphoma offer little to no value. Prognostic value is also difficult to identify for an interim positron emission tomography-computed tomography scan during induction therapy for diffuse large B-cell lymphoma (cited Mamot et al. as reference 2, Thompson et al. as reference 3, El-Galaly et al. as reference 4, and Huntington et al. as reference 5).
Revised text to state that favorable survival after relapse has been associated with an age younger than 60 years, complete remission rather than partial remission, and duration of response longer than 2 year (cited Casulo et al. as reference 1).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summaryand PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: November 22, 2016

No hay comentarios:

Publicar un comentario en la entrada